PBSS Free Online Symposium: Oxbryta ® (Voxelotor) Tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned

Building upon nearly 70 years of research in sickle cell disease (SCD) pathology, voxelotor, an HbS polymerization inhibitor, was developed to treat
the root cause of SCD pathophysiology. In 2019, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin, a biologic surrogate endpoint, indicative of reduced SCD hemolysis. In this presentation, we will share the R&D journey of Oxbryta®.

This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association)